Mesalazine reduces mutations in transforming growth factor beta receptor II and activin type II receptor by improvement of replication fidelity in mononucleotide repeats
- PMID: 20197483
- PMCID: PMC3437339
- DOI: 10.1158/1078-0432.CCR-09-2854
Mesalazine reduces mutations in transforming growth factor beta receptor II and activin type II receptor by improvement of replication fidelity in mononucleotide repeats
Abstract
Purpose: Mesalazine (5-aminosalicylic acid, 5-ASA) has chemopreventive properties in colitis-associated cancer. In vitro, it improves replication fidelity at (CA)13 microsatellites independent of mismatch repair proficiency. Therefore, 5-ASA might be advantageous in patients with hereditary nonpolyposis colorectal cancer. At this point, however, it is uncertain whether this improvement of replication fidelity is specific for (CA)13 repetitive sequences. Here, we tested the effect of 5-ASA on replication fidelity in mononucleotide, dinucleotide, and tetranucleotide repeats.
Experimental design: HCT116 and HCT116+chr3 cells were transfected with pIREShyg2-EGFP reporter plasmids harboring the following microsatellites: A10, G10, (CA)13, (CA)26, (AAAG)17, poly-A tracts, and their flanking sequences of transforming growth factor beta receptor II (TGFBR2; A10) and activin type II receptor (ACVR2; A8). Stably transfected single-cell clones were selected, characterized by Southern blotting, sorted into six-well plates, and cultured with or without 5-ASA. Frameshift mutations that shift the enhanced green fluorescence protein into its proper reading frame were quantified by flow cytometry.
Results: In HCT116, 5-ASA reduced the mutant fraction at (CA)13 by 48.3%, at A10 by 35.6-43.6%, at G10 by 74.9-83.6%, and at (AAAG)17 by 37.6-44.4%. Similar results were observed in hMLH1-proficient HCT116+chr3 cells. Moreover, the presence of 5-ASA significantly reduced mutations in TGFBR2 (A10) and ACVR2 (A8) by 39.9% and 46.2%, respectively.
Conclusions: 5-ASA increases replication fidelity in mononucleotide, dinucleotide, and tetranucleotide repeats and reduces mutations in tumor suppressor genes TGFBR2 and ACVR2, a finding that may provoke in vivo studies for the prevention of colorectal cancer in hereditary nonpolyposis colorectal cancer.
Conflict of interest statement
C. Gasche has research collaborations with Giuliani SpA and Shire Pharmaceuticals. The other authors do not have a conflict of interest to report.
Figures




Similar articles
-
Both microsatellite length and sequence context determine frameshift mutation rates in defective DNA mismatch repair.Hum Mol Genet. 2010 Jul 1;19(13):2638-47. doi: 10.1093/hmg/ddq151. Epub 2010 Apr 23. Hum Mol Genet. 2010. PMID: 20418486 Free PMC article.
-
Mutation rates of TGFBR2 and ACVR2 coding microsatellites in human cells with defective DNA mismatch repair.PLoS One. 2008;3(10):e3463. doi: 10.1371/journal.pone.0003463. Epub 2008 Oct 21. PLoS One. 2008. PMID: 18941508 Free PMC article.
-
Mesalazine improves replication fidelity in cultured colorectal cells.Cancer Res. 2005 May 15;65(10):3993-7. doi: 10.1158/0008-5472.CAN-04-3824. Cancer Res. 2005. PMID: 15899787
-
The nucleotide composition of microsatellites impacts both replication fidelity and mismatch repair in human colorectal cells.Hum Mol Genet. 2010 Jul 1;19(13):2648-57. doi: 10.1093/hmg/ddq175. Epub 2010 Apr 26. Hum Mol Genet. 2010. PMID: 20421367 Free PMC article.
-
Flanking nucleotide specificity for DNA mismatch repair-deficient frameshifts within activin receptor 2 (ACVR2).Mutat Res. 2012 Jan 3;729(1-2):73-80. doi: 10.1016/j.mrfmmm.2011.09.009. Epub 2011 Oct 5. Mutat Res. 2012. PMID: 22001236 Free PMC article.
Cited by
-
The Role of the Immune System in IBD-Associated Colorectal Cancer: From Pro to Anti-Tumorigenic Mechanisms.Int J Mol Sci. 2021 Nov 25;22(23):12739. doi: 10.3390/ijms222312739. Int J Mol Sci. 2021. PMID: 34884543 Free PMC article. Review.
-
The 5-aminosalicylic acid antineoplastic effect in the intestine is mediated by PPARγ.Carcinogenesis. 2013 Nov;34(11):2580-6. doi: 10.1093/carcin/bgt245. Epub 2013 Jul 10. Carcinogenesis. 2013. PMID: 23843037 Free PMC article.
-
Colorectal cancer chemoprevention by mesalazine and its derivatives.J Biomed Biotechnol. 2012;2012:980458. doi: 10.1155/2012/980458. Epub 2012 Jun 4. J Biomed Biotechnol. 2012. PMID: 22701310 Free PMC article. Review.
-
Does the expression of the ACVR2A gene affect the development of colorectal cancer?Genet Mol Biol. 2019 Jan-Mar;42(1):32-39. doi: 10.1590/1678-4685-GMB-2017-0332. Epub 2019 Mar 11. Genet Mol Biol. 2019. PMID: 30856244 Free PMC article.
-
New sights of immunometabolism and agent progress in colitis associated colorectal cancer.Front Pharmacol. 2024 Jan 11;14:1303913. doi: 10.3389/fphar.2023.1303913. eCollection 2023. Front Pharmacol. 2024. PMID: 38273841 Free PMC article. Review.
References
-
- Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol. 2004;287:G7–17. - PubMed
-
- Croog VJ, Ullman TA, Itzkowitz SH. Chemoprevention of colorectal cancer in ulcerative colitis. Int J Colorectal Dis. 2003;18:392–400. - PubMed
-
- Rubin DT, Cruz-Correa MR, Gasche C, et al. Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. Inflamm Bowel Dis. 2007;14:265–274. - PubMed
-
- Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005;100:1345–1353. - PubMed
-
- Velayos FS, Loftus EV, Jr, Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology. 2006;130:1941–1949. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical